Long-term renal effects of tenofovir-disoproxil-fumarate in vertically HIV-infected children, adolescents, and young adults: A 132-month follow-up study

Clinical Drug Investigation

Volumn 35, Issue 7, 2015, Pages 419-426

  Giacomet, Vania ^a   Nannini, Pilar ^a   Vigano, Alessandra ^a   Erba, Paola ^a   Benincaso, Annarita ^a   Bedogni, Giorgio ^b   Cattaneo, Dario ^a   Falvella, Felicia Stefania ^a   Zuccotti, Gian Vincenzo ^c  

^a UNIVERSITY OF MILAN   (Italy)

^b Liver Research Center   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; EFAVIRENZ; EMTRICITABINE; LAMIVUDINE; PHOSPHATE; PROTEINASE INHIBITOR; TENOFOVIR DISOPROXIL; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; TENOFOVIR;

ABCC2 GENE; ADOLESCENT; ADULT; ANTHROPOMETRIC PARAMETERS; ARTICLE; BODY HEIGHT; BODY MASS; BODY WEIGHT; CD4 LYMPHOCYTE COUNT; CHILD; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DRUG SAFETY; FEMALE; FOLLOW UP; GENE; GENE MAPPING; GENOTYPE; GLOMERULUS FILTRATION RATE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; KIDNEY FUNCTION; LABORATORY; MALE; OUTCOME ASSESSMENT; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; VIRUS LOAD; YOUNG ADULT; DRUG EFFECTS; HIV INFECTIONS; INFANT; KIDNEY; NEWBORN; PRESCHOOL CHILD; VIROLOGY;

ANTI-HIV AGENTS; CHILD; CHILD, PRESCHOOL; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HIV INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; KIDNEY; MALE; TENOFOVIR; VIRAL LOAD;

EID: 84982902911     PISSN: 11732563     EISSN: 11791918     Source Type: Journal    
DOI: 10.1007/s40261-015-0293-7     Document Type: Article

References (37)

1. Patel K, Hernán MA, Williams PL, et al. Long-term effectiveness of highly active antiretroviral therapy on the survival of children and adolescents with HIV infection: a 10-year follow-up study. Clin Infect Dis. 2008;46:507-15.
2. Viganò A, Bedogni G, Manfredini V, et al. Long-term renal safety of tenofovirdisoproxilfumarate in vertically HIV-infected children, adolescents and young adults: a 60-month follow-up study. Clin Drug Invest. 2011;31(6):407-15.
3. Atripla: highlight of prescribing information. Available at: http://packageinserts.bms.com/pi/pi_atripla.pdf. Accessed 12 Jan 2013
4. Stribild: highlight of prescribing information. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203100s000lbl.pdf. Accessed 12 Jan 2013.
5. Gilead Science 2006 annual report on marketed products. 2007. Available at: http://www.gilead.ca/AR2006/hiv_aids.php Accessed 9 Sept 2013.
6. Riordan A, Judd A, Boyd K, et al. Tenofovir use in human immunodeficiency virus-1-infected children in the United Kingdom and Ireland. Pediatr Infect Dis J. 2009;28:204-9.
7. Hawkins S, Ball C. Adverse events experienced by three children taking tenofovir and didanosine in combination. HIV Med. 2007;8:411.
8. Andiman WA, Chernoff MC, Mitchell C, et al. Incidence of persistent renal dysfunction in human immunodeficiency virusinfected children: associations with the use of antiretrovirals, and other nephrotoxic medications and risk factors. Pediatr Infect Dis J. 2009;28:619-25.
9. Purswani M, Patel K, Kopp JB, et al. Tenofovir treatment duration predicts proteinuria in a multi-ethnic United States cohort of children and adolescents with perinatal HIV-1 infection. Pediatr Infect Dis J. 2013;32:495-500.
10. Viganò A, Zuccotti GV, Martelli L, et al. Renal safety of tenofovir in HIV-infected children: a prospective, 96-week longitudinal study. Clin Drug Invest. 2007;27:573-81.
11. Judd A, Boyd KL, Stohr W, et al. Effect of tenofovirdisoproxil-fumarate on risk of renal abnormality in HIV-1-infected children on antiretroviral therapy: a nested case-control study. AIDS. 2010;24:525-34.
12. Peyrière H, Reynes J, Rouanet I, et al. Renal tubular dysfunction associated with tenofovir therapy: report of 7 cases. J Acquir Immune Defic Syndr. 2004;35:269-73.
13. Hussain S, Khayat A, Tolaymat A, et al. Nephrotoxicity in a child with perinatal HIV on tenofovir, didanosine and lopinavir/ritonavir. Pediatr Nephrol. 2006;21:1034-6.
14. Hogg RJ, Furth S, Lemley KV, et al. National Kidney Foundation’s Kidney Disease Outcomes Quality Initiative clinical practice guidelines for chronic kidney disease in children and adolescents: evaluation, classification, and stratification. Pediatrics. 2003;111:1416-21.
15. Schwartz GJ, Munoz A, Schneider MF, et al. New equations to estimate GFR in children with CKD. J Am Soc Nephrol. 2009;20:629-37.
16. Izzedine H, Hulot JS, Vittecoq D, et al. Long-term renal safety of tenofovir disoproxil fumarate in antiretroviral-naïve HIV-1-in-fected patients: data from a double blind randomized activecontrolled multicenter study. Nephrol Dial Transplant. 2005;20:743-6.
17. Hardin JW, Hilbe JM. Generalized estimating equations. Generalized estimating equations. Boca Raton: CRC Press; 2013.
18. Abitbol CL, Strauss J, Zilleruelo G, et al. Validity of random urines to quantitate proteinuria in children with human immunodeficiency virus nephropathy. Pediatr Nephrol. 1996;10:598-601.
19. Royston P, Sauerbrei W. Multivariable model-building: a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables. Multivariable model-building: a pragmatic approach to regression analysis based on fractional polynomials for modelling continuous variables. Chichester: Wiley; 2008
20. Cooper RD, Wiebe N, Smith N, et al. Systematic review and meta-analysis: renal safety of tenofovirdisoproxilfumarate in HIV-infected patients. Clin Infect Dis. 2010;51:496-505.
21. Nishijima T, Komatsu H, Gatanaga H, et al. Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients. PLoS One. 2011;6:e22661.
22. Chaisiri K, Bowonwatanuwong C, Kasettratat N, et al. Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight. Curr HIV Res. 2010;8:504-9
23. Tourret J, Deray G, Isnard-Bagnis C. Tenofovir effect on the kidneys of HIV-infected patients: a double-edged sword? JASN. 2013;24:1519-27.
24. Soler-Palacín P, et al. Prospective study of renal function in HIV-infected pediatric patients receiving tenofovir-containing HAART regimens. AIDS. 2011;25(2):171-6.
25. Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS. 2008;22:99-103.
26. Nelson MR, Katlama C, Montaner JS, et al. The safety of tenofovirdisoproxilfumarate for the treatment of HIV infection in adults: the first 4 years. AIDS. 2007;21:1273-81.
27. Stohr W, Reid A, Walker AS, et al. Glomerular dysfunction and associated risk factors over 4-5 years following antiretroviral therapy initiation in Africa. Antivir Ther. 2011;16:1011-20.
28. Atefeh J, Hossein K, Dashti-Khavidaki S. Tenofovir-induced nephrotoxicity: incidence, mechanism, risk factors, prognosis and proposed agents for prevention. Eur J Clin Pharmacol. 2014;70:1029-40.
29. Aurpibul L, Puthanakit T. Review of tenofovir use in HIV-in-fected children. Pediatr Infect Dis J. 2015;34:383-91.
30. Giacomet V, Cattaneo D, Viganò A, et al. Tenofovir-induced renal tubular dysfunction in vertically HIV-infected patients associated with polymorphisms in ABCC2, ABCC4 and ABCC10 genes. Ped Infect Dis J. 2013;32:e403-5.
31. Saez-Llorens X, Castano E, Rathore M, et al. A randomized, open-label study of the safety and efficacy of switching stavudine or zidovudine to tenofovirdisoproxilfumarate in human immunodeficiency virus-1 infected children with virologic suppression. Pediatr Infect Dis J. 2014;. doi:10.1097/INF.0000000000000289.
32. Aurpibul L, Narkbunnam T, Sirisanthana V, et al. 48-week safety of tenofovir when administered according to weight band dosing in HIV-infected children C 15 kg as part of a once-daily HAART regimen. Abstract no v-112. In: 20th conference on retroviruses and opportunistic infections. March 5 to 8, 2013. Georgia, Atlanta.
33. Della Negra M, de Carvalho AP, de Aquino MZ, et al. A randomized study of tenofovirdisoproxilfumarate in treatment-experienced HIV-1 infected adolescents. Pediatr Infect Dis J. 2012;31:469-73
34. Weerawat M, Chonlaphat S, Supeda T, et al. ABCC2*1C and plasma tenofovir concentration are collated to decreased glomerular filtration rate in patients receiving a tenofovir-containing antiretroviral regimen. J Antimicrob Chemother. 2014;69:2195-201.
35. Nishijima T, Komatsu H, Higasa K, et al. Single nucleotide polymorphisms in ABCC2 associate with tenofovir-induced kidney tubular dysfunction in Japanese patients with HIV-1 infection: a pharmacogenetic study. Clin Infect Dis. 2012;55:1558-67.
36. Rodríguez-Nóvoa S, Labarga P, Soriano V, et al. Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study. Clin Infect Dis. 2009;48:e108-16.
37. Izzedine H, Hulot JS, Villard E. Association between ABCC2 gene haplotypes and tenofovir-induced proximal tubulopathy. J Infect Dis. 2006;194:1481-91